Chengdu Kanghua Biological Products Asset Resilience Ratio
Chengdu Kanghua Biological Products asset resilience ratio. Chengdu Kanghua Biological Products (300841) has an Asset Resilience Ratio of 1.19% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chengdu Kanghua Biological Products (300841) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chengdu Kanghua Biological Products (2020–2020)
Asset resilience ratio of Chengdu Kanghua Biological Products from 2020 to 2020. This chart shows how Chengdu Kanghua Biological Products's Asset Resilience Ratio has changed over time. Read Chengdu Kanghua Biological Products total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Kanghua Biological Products's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300841 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥50.00 Million | 1.19% |
| Total Liquid Assets | CN¥50.00 Million | 1.19% |
Asset Resilience Insights
- Limited Liquidity: Chengdu Kanghua Biological Products maintains only 1.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Kanghua Biological Products Industry Peers by Asset Resilience Ratio
Compare Chengdu Kanghua Biological Products's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Chengdu Kanghua Biological Products Asset Resilience Ratio by Year (2020–2020)
Chengdu Kanghua Biological Products asset resilience ratio by year from 2020 to 2020. The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghua Biological Products.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 8.38% | CN¥180.00 Million ≈ $26.34 Million |
CN¥2.15 Billion ≈ $314.27 Million |
-- |
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more